Ieq Capital LLC lifted its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 1,425.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 126,710 shares of the company’s stock after acquiring an additional 118,404 shares during the period. Ieq Capital LLC’s holdings in Apellis Pharmaceuticals were worth $4,043,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of APLS. Wolverine Asset Management LLC purchased a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $27,000. True Wealth Design LLC purchased a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $27,000. Capital Performance Advisors LLP purchased a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $56,000. KBC Group NV raised its holdings in shares of Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after buying an additional 679 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after buying an additional 781 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Apellis Pharmaceuticals
In other news, insider Caroline Baumal sold 2,816 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the completion of the transaction, the insider now owns 55,560 shares of the company’s stock, valued at approximately $1,878,483.60. This represents a 4.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Cedric Francois sold 2,824 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total value of $83,364.48. Following the completion of the transaction, the chief executive officer now directly owns 415,695 shares of the company’s stock, valued at approximately $12,271,316.40. The trade was a 0.67 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 60,365 shares of company stock valued at $1,810,479. 6.80% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Get Our Latest Stock Report on Apellis Pharmaceuticals
Apellis Pharmaceuticals Price Performance
Shares of APLS opened at $27.52 on Friday. The company has a market cap of $3.42 billion, a P/E ratio of -13.56 and a beta of 0.96. The stock has a fifty day moving average price of $30.61 and a 200 day moving average price of $31.87. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $71.90.
Apellis Pharmaceuticals Profile
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
Read More
- Five stocks we like better than Apellis Pharmaceuticals
- What is Put Option Volume?
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- The Most Important Warren Buffett Stock for Investors: His Own
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report).
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.